Clinical Trial Update: Anecortave Acetate Risk-Reduction Trial (AART) [Phase 3]

View source ↗

Summary

The Phase 3 Anecortave Acetate Risk-Reduction Trial (AART) for age-related macular degeneration was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• anecortave acetate (anecortave acetate)

Snippet

Sponsor: Alcon Research | Conditions: AMD | Phase 3 | Status: TERMINATED